Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib in Newly Diagnosed CML-CP (MACS1252)
NCT01061177Phase 4Completed
- Sponsor
- Novartis
- Start
- May 2010
- Primary completion
- Jul 2014
- Modality
- Small Molecules
- Countries
- 26
01
Overview
A Phase 4 trial of nilotinib in chronic myeloid leukemia (CML), sponsored by Novartis. Started May 2010; status: completed.
02
Drugs
nilotinib
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01061177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01061177.